Published Year: 2023
Next Generation Sequencing (NGS) Market - A Global and Regional Analysis: Focus on Offering, Company
The global NGS market was valued at $6.76 billion in 2022 and is expected to reach $28.47...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Research Methodology
1.3.1 Global Cancer Microbiome Sequencing Market: Research Methodology
1.3.2 Data Sources
1.3.2.1 Primary Data Sources
1.3.2.2 Secondary Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling
1.4 Market Overview
1.4.1 Market Definition
1.4.2 Market Footprint and Growth Potential, $Million, 2020-2031
1.4.3 Impact of COVID-19 on the Global Cancer Microbiome Sequencing Market
2.1 Overview
2.2 Legal Requirements and Framework in the U.S.
2.3 Legal Requirements and Framework in Europe
2.4 Legal Requirements and Framework in Asia-Pacific
2.4.1 China
2.4.2 Japan
3.1 Overview
3.2 Iceberg Analysis – Global Cancer Microbiome Sequencing Market
3.3 Impact Analysis
3.4 Market Drivers
3.4.1 Increasing Emphasis on the Microbiome’s Potential in the Field of Cancer
3.4.2 Global Increase in Cancer Prevalence
3.4.3 Decreasing Cost of Sequencing
3.5 Market Restraints
3.5.1 Regulatory Challenges for Direct-to-Consumer (DTC) Companies
3.5.2 Lack of High Complexity Testing Centers
3.5.3 Existing Diagnostic Confidence on Conventional Cancer Diagnostics
3.6 Market Opportunities
3.6.1 Growing Integrative Industry-Academia Collaboration
3.6.2 Massive Scope for Adoption of Cancer Microbiome Sequencing in Developing Nations
4.1 Overview
4.2 Synergistic Activities
4.3 Product Launches
4.4 Funding
4.5 Product Approval
4.6 Acquisitions
4.7 Market Share Analysis, 2019–2020
4.8 Growth Share Analysis
5.1 Overview
5.2 Product
5.2.1 Kits and Assays
5.2.2 Software
5.3 Service
6.1 Overview
6.2 Translational Research
6.3 Diagnostics
6.3.1 Colorectal Cancer (CRC)
6.3.2 Cervical Cancer
6.3.3 Oral Cancer
6.3.4 Other Cancer Types
7.1 Overview
7.2 Next-Generation Sequencing (NGS)
7.2.1 Sequencing by Synthesis (SBS)
7.2.2 Sequencing by Ligation (SBL)
7.2.3 Other Next-Generation Sequencing (NGS) Technologies
7.3 Polymerase Chain Reaction (PCR)
8.1 Overview
8.2 Academic and Research Institutes
8.3 Pharmaceutical and Biotechnology Companies
8.4 Hospitals and Diagnostic Laboratories
8.5 Other End Users
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 U.K.
9.3.4 Spain
9.3.5 Italy
9.3.6 Switzerland
9.3.7 Rest-of-Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Singapore
9.4.7 Rest-of-Asia-Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest-of-Latin America (RoLA)
9.6 Rest-of-the-World
10.1 Overview
10.2 CD Genomics
10.2.1 Company Overview
10.2.2 Role of CD Genomics in the Global Cancer Microbiome Sequencing Market
10.2.3 SWOT Analysis
10.3 Eurofins Scientific
10.3.1 Company Overview
10.3.2 Role of Eurofins Scientific in the Global Cancer Microbiome Sequencing Market
10.3.3 Financials
10.3.4 SWOT Analysis
10.4 GoodGut
10.4.1 Company Overview
10.4.2 Role of GoodGut in the Global Cancer Microbiome Sequencing Market
10.4.3 SWOT Analysis
10.5 Illumina, Inc.
10.5.1 Company Overview
10.5.2 Role of Illumina, Inc. in the Global Cancer Microbiome Sequencing Market
10.5.3 Financials
10.5.4 Key Insights About Financial Health of the Company
10.5.5 SWOT Analysis
10.6 Prescient Medicine Holdings, Inc.
10.6.1 Company Overview
10.6.2 Role of Prescient Medicine Holdings, Inc. in the Global Cancer Microbiome Sequencing Market
10.6.3 SWOT Analysis
10.7 Micronoma Inc.
10.7.1 Company Overview
10.7.2 Role of Micronoma Inc. in the Global Cancer Microbiome Sequencing Market
10.7.3 SWOT Analysis
10.8 Novogene Co., Ltd.
10.8.1 Company Overview
10.8.2 Role of Novogene Co., Ltd. in the Global Cancer Microbiome Sequencing Market
10.8.3 SWOT Analysis
10.9 Oxford Nanopore Technologies plc.
10.9.1 Company Overview
10.9.2 Role of Oxford Nanopore Technologies plc. in the Global Cancer Microbiome Sequencing Market
10.9.3 Financials
10.9.4 Key Insights About Financial Health of the Company
10.9.5 SWOT Analysis
10.10 OraSure Technologies, Inc.
10.10.1 Company Overview
10.10.2 Role of OraSure Technologies, Inc. in the Global Cancer Microbiome Sequencing Market
10.10.3 Financials
10.10.4 Key Insights About Financial Health of the Company
10.10.5 SWOT Analysis
10.11 Pacific Biosciences of California, Inc.
10.11.1 Company Overview
10.11.2 Role of Pacific Biosciences of California, Inc. in the Global Cancer Microbiome Sequencing Market
10.11.3 Financials
10.11.4 Key Insights About Financial Health of the Company
10.11.5 SWOT Analysis
10.12 Psomagen, Inc.
10.12.1 Company Overview
10.12.2 Role of Psomagen, Inc. in the Global Cancer Microbiome Sequencing Market
10.12.3 Financials
10.12.4 Key Insights About Financial Health of the Company
10.12.5 SWOT Analysis
10.13 QIAGEN N.V.
10.13.1 Company Overview
10.13.2 Role of QIAGEN N.V. in the Global Cancer Microbiome Sequencing Market
10.13.3 Financials
10.13.4 Key Insights About Financial Health of the Company
10.13.5 SWOT Analysis
10.14 Thermo Fisher Scientific Inc.
10.14.1 Company Overview
10.14.2 Role of Thermo Fisher Scientific Inc. in the Global Cancer Microbiome Sequencing Market
10.14.3 Financials
10.14.4 Key Insights About Financial Health of the Company
10.14.5 SWOT Analysis
10.15 Viome, Inc.
10.15.1 Company Overview
10.15.2 Role of Viome, Inc. in the Global Cancer Microbiome Sequencing Market
10.15.3 SWOT Analysis
10.16 Zymo Research Corporation
10.16.1 Company Overview
10.16.2 Role of Zymo Research Corporation in the Global Cancer Microbiome Sequencing Market
10.16.3 SWOT Analysis
Table 1: Likert Scale
Table 2: Impact Analysis of Market Drivers
Table 3: Impact Analysis of Market Restraints
Table 4: North America: Market Dynamics
Table 5: Europe: Market Dynamics
Table 6: APAC: Market Dynamics
Table 7: Latin America: Market Dynamics
Figure 1: Annual NIH Funding for Microbiome Research, $Million, FY2007-FY2016
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Cancer Microbiome Sequencing Market
Figure 3: Global Cancer Microbiome Sequencing Market (by Offering), $Million, 2020 and 2031
Figure 4: Global Cancer Microbiome Sequencing Market (by Application), $Million, 2020 and 2031
Figure 5: Global Cancer Microbiome Sequencing Market (by Technology), 2020 and 2021
Figure 6: Global Cancer Microbiome Sequencing Market (by End User), $Million, 2020 and 2031
Figure 7: Global Cancer Microbiome Sequencing Market Snapshot
Figure 8: Global Cancer Microbiome Sequencing Market: Segmentation
Figure 9: Global Cancer Microbiome Sequencing Market: Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Top-Down Approach (Segment-Wise Analysis)
Figure 13: Global Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 14: Global Cancer Microbiome Sequencing Market: COVID-19 Impact Analysis
Figure 15: Assessment of Commercialization Strategy in China
Figure 16: Assessment of Commercialization Strategy in Japan
Figure 17: Iceberg Analysis – Global Cancer Microbiome Sequencing Market
Figure 18: Global Cancer Burden, 2018
Figure 19: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 20: Share of Key Developments and Strategies, January 2018-September 2021
Figure 21: Share of Synergistic Activities (by Company), January 2018-November 2021
Figure 22: Number of Product Launches (by Company), January 2018–November 2021
Figure 23: Share of Funding Activities (by Company), January 2018-November 2021
Figure 24: Share of Product Approvals (by Company), January 2018-November 2021
Figure 25: Market Share Analysis for Global Cancer Microbiome Sequencing Market, $Million, 2019 and 2020
Figure 26: Growth Share Analysis for Global Cancer Microbiome Sequencing Market (by Company), 2020
Figure 27: Global Cancer Microbiome Sequencing Market (by Offering)
Figure 28: Global Cancer Microbiome Sequencing Market (by Offering), 2020 and 2031
Figure 29: Global Cancer Microbiome Sequencing Market (by Product), $Million, 2020-2031
Figure 30: Global Cancer Microbiome Sequencing Market (by Product), $Million, 2020-2031
Figure 31: Global Cancer Microbiome Sequencing Market (Kits and Assays), $Million, 2020-2031
Figure 32: Global Cancer Microbiome Sequencing Market (Software), $Million, 2020-2031
Figure 33: Global Cancer Microbiome Sequencing Market (Service), $Million, 2020-2031
Figure 34: Global Cancer Microbiome Sequencing Market (by Application)
Figure 35: Global Cancer Microbiome Sequencing Market (by Application), $Million, 2020–2031
Figure 36: Global Cancer Microbiome Sequencing Market (Translational Research), $Million, 2020-2031
Figure 37: Global Cancer Microbiome Sequencing Market (Diagnostics), $Million, 2020-2031
Figure 38: Global Cancer Microbiome Sequencing Market (by Diagnostics), 2020 and 2031
Figure 39: Global Cancer Microbiome Sequencing Market (CRC), $Million, 2020-2031
Figure 40: Global Cancer Microbiome Sequencing Market (Cervical Cancer), $Million, 2020-2031
Figure 41: Global Cancer Microbiome Sequencing Market (Oral Cancer), $Million, 2020-2031
Figure 42: Global Cancer Microbiome Sequencing Market (Other Cancer Types), $Million, 2020-2031
Figure 43: Global Cancer Microbiome Sequencing Market (by Technology)
Figure 44: Global Cancer Microbiome Sequencing Market (by Technology), 2020 and 2021
Figure 45: Global Cancer Microbiome Sequencing Market (by Next-Generation Sequencing), $Million, 2020-2031
Figure 46: Global Cancer Microbiome Sequencing Market (Sequencing by Synthesis), $Million, 2020-2031
Figure 47: Global Cancer Microbiome Sequencing Market (Sequencing by Ligation), $Million, 2020-2031
Figure 48: Global Cancer Microbiome Sequencing Market (Other NGS Technologies), $Million, 2020-2031
Figure 49: Global Cancer Microbiome Sequencing Market (Polymerase Chain Reaction), $Million, 2020-2031
Figure 50: Global Cancer Microbiome Sequencing Market (by End User)
Figure 51: Global Cancer Microbiome Sequencing Market (by End User), $Million, 2020–2031
Figure 52: Global Cancer Microbiome Sequencing Market (Academic and Research Institutions), $Million, 2020-2031
Figure 53: Global Cancer Microbiome Sequencing Market (Pharmaceutical and Biotechnology Companies), $Million, 2020-2031
Figure 54: Global Cancer Microbiome Sequencing Market (Hospitals and Diagnostic Laboratories), $Million, 2020-2031
Figure 55: Global Cancer Microbiome Sequencing Market (Other End Users), $Million, 2020-2031
Figure 56: Global Cancer Microbiome Sequencing (by Region): Market Snapshot
Figure 57: Global Cancer Microbiome Sequencing Market (by Region), $Million, 2020-2031
Figure 58: Global Cancer Microbiome Sequencing Market (by Region), 2020 and 2031
Figure 59: North America Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 60: North America Cancer Microbiome Sequencing Market (by Country), $Million, 2020-2031
Figure 61: U.S. Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 62: Canada Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 63: Europe Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 64: Europe Cancer Microbiome Sequencing Market (by Country), $Million, 2020–2031
Figure 65: Germany Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 66: France Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 67: U.K. Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 68: Spain Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 69: Italy Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 70: Switzerland Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 71: Rest-of-Europe Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 72: Asia-Pacific Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 73: APAC Cancer Microbiome Sequencing Market (by Country), $Million, 2020-2031
Figure 74: China Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 75: Japan Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 76: India Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 77: Australia Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 78: South Korea Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 79: Singapore Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 80: RoAPAC Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 81: Latin America Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 82: Latin America Cancer Microbiome Sequencing Market (by Country), $Million, 2020-2031
Figure 83: Brazil Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 84: Mexico Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 85: Rest-of-Latin America Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 86: Rest-of-the-World Cancer Microbiome Sequencing Market, $Million, 2020-2031
Figure 87: Total Number of Companies Profiled
Figure 88: CD Genomics: Product Portfolio
Figure 89: CD Genomics: SWOT Analysis
Figure 90: Eurofins Scientific: Portfolio
Figure 91: Eurofins Scientific: Overall Financials, 2018-2020
Figure 92: Eurofins Scientific: Revenue (by Region), 2018-2020
Figure 93: Eurofins Scientific: SWOT Analysis
Figure 94: GoodGut: Portfolio
Figure 95: GoodGut: SWOT Analysis
Figure 96: Illumina, Inc.: Product Portfolio
Figure 97: Illumina, Inc.: Overall Financials, 2018-2020
Figure 98: Illumina, Inc.: Revenue (by Business Segment), 2018–2020
Figure 99: Illumina, Inc.: Revenue (by Region), 2018–2020
Figure 100: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 101: Illumina, Inc.: SWOT Analysis
Figure 102: Prescient Medicine Holdings, Inc.: Product Portfolio
Figure 103: Prescient Medicine Holdings, Inc.: SWOT Analysis
Figure 104: Micronoma Inc.: Product Portfolio
Figure 105: Micronoma Inc.: SWOT Analysis
Figure 106: Novogene Co., Ltd.: Product Portfolio
Figure 107: Novogene Co., Ltd.: SWOT Analysis
Figure 108: Oxford Nanopore Technologies plc.: Product Portfolio
Figure 109: Oxford Nanopore Technologies plc.: Overall Financials, 2018-2020
Figure 110: Oxford Nanopore Technologies plc.: Revenue (by Business Segment), 2018–2020
Figure 111: Oxford Nanopore Technologies plc.: Revenue (by Region), 2018–2020
Figure 112: Oxford Nanopore Technologies plc.: R&D Expenditure, 2018 - 2020
Figure 113: Oxford Nanopore Technologies plc.: SWOT Analysis
Figure 114: OraSure Technologies, Inc.: Product Portfolio
Figure 115: OraSure Technologies, Inc.: Overall Financials, 2018-2020
Figure 116: OraSure Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 117: OraSure Technologies, Inc.: Revenue (by Molecular Solutions), 2019-2020
Figure 118: OraSure Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 119: OraSure Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 120: OraSure Technologies, Inc.: SWOT Analysis
Figure 121: Pacific Biosciences of California, Inc.: Product Portfolio
Figure 122: Pacific Biosciences of California, Inc.: Overall Financials, 2018-2020
Figure 123: Pacific Biosciences of California, Inc.: Revenue (by Business Segment), 2018–2020
Figure 124: Pacific Biosciences of California, Inc.: Revenue (by Region), 2018–2020
Figure 125: Pacific Biosciences of California, Inc.: R&D Expenditure, 2018-2020
Figure 126: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 127: Psomagen, Inc.: Portfolio
Figure 128: Psomagen, Inc.: Overall Financials, 2018-2020
Figure 129: Psomagen, Inc.: Revenue (by Business Segment), 2018–2020
Figure 130: Psomagen, Inc.: Revenue (by Region), 2019–2020
Figure 131: Psomagen, Inc.: R&D Expenditure, 2018-2020
Figure 132: Psomagen, Inc.: SWOT Analysis
Figure 133: QIAGEN N.V.: Product Portfolio
Figure 134: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 135: QIAGEN N.V.: Revenue (by Business Segment), 2018–2020
Figure 136: QIAGEN N.V.: Revenue (by Region), 2018–2020
Figure 137: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 138: QIAGEN N.V.: SWOT Analysis
Figure 139: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 140: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 141: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018–2020
Figure 142: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018–2020
Figure 143: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 144: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 145: Viome, Inc.: Product Portfolio
Figure 146: Viome, Inc.: SWOT Analysis
Figure 147: Zymo Research Corporation: Product Portfolio
Figure 148: Zymo Research Corporation: SWOT Analysis
Market Report Coverage
|
Cancer Microbiome Sequencing Market |
|||
|
Base Year |
2020 |
Market Size in 2020 |
$155.5 Million |
|
Forecast Period |
2021-2031 |
Value Projection and Estimation by 2031 |
$1,216.2 Million |
|
CAGR During Forecast Period |
20.01% |
Number of Table |
07 |
|
Number of Pages |
187 |
Number of Figures |
148 |
|
Market Segmentation |
• Offering– Product (Kits and Assays and Software) and Service • Application– Translational Research and Diagnostics (Colorectal Cancer, Cervical Cancer, Oral Cancer, and Other Cancer Types) • Technology – Next-Generation Sequencing (Sequencing by Synthesis, Sequencing by Ligation, and Other Next-Generation Sequencing Technologies) and Polymerase Chain Reaction • End User – Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Laboratories, and Other End Users |
||
|
Regional Segmentation |
• North America – U.S., and Canada • Europe – Germany, France, U.K., Spain, Italy, Switzerland, and Rest-of-Europe • Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific • Latin America – Brazil, Mexico, and Rest-of-Latin America • Rest-of-the-World |
||
|
Market Growth Drivers |
• Increasing Emphasis on the Microbiome’s Potential in the Field of Cancer • Global Increase in Cancer Prevalence • Decreasing Cost of Sequencing |
||
|
Market Challenges |
• Regulatory Challenges for Direct-to-Consumer (DTC) Companies • Lack of High Complexity Testing Centers • Existing Diagnostic Confidence on Conventional Cancer Diagnostics |
||
|
Market Opportunities |
• Growing Integrative Industry-Academia Collaboration • Massive Scope for Adoption of Cancer Microbiome Sequencing in Developing Nations |
||
|
Key Companies Profiled |
CD Genomics, Eurofins Scientific, GoodGut, Illumina, Inc., Prescient Medicine Holdings, Inc., Micronoma Inc., Novogene Co., Ltd., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Viome, Inc., Zymo Research Corporation |
||
Key Questions Answered in this Report:
• How is cancer microbiome sequencing revolutionizing the field of oncology?
• What are the major market drivers, challenges, and opportunities in the global cancer microbiome sequencing market?
• What are the underlying structures resulting in the emerging trends within the global cancer microbiome sequencing market?
• How did the COVID-19 pandemic impact the global cancer microbiome sequencing ecosystem?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of cancer microbiome sequencing?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Offering (product and service)
o Application (translational research and diagnostics)
o Technology (next-generation sequencing and polymerase chain reaction)
o End User (academic and research institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the cancer microbiome sequencing companies in the region of their operation?
• Who are the leading players with significant offerings in the global cancer microbiome sequencing market?
• Which companies are anticipated to be highly disruptive in the future, and why?
Report Summary
Market Overview
Our healthcare experts have found the cancer microbiome sequencing industry to be one of the most rapidly evolving and dynamic markets, and the global market for cancer microbiome sequencing is predicted to grow at a CAGR of 20.01% over the forecast period of 2021-2031. The market is driven by certain factors, including increasing emphasis on the microbiome’s potential in cancer, global increase in cancer prevalence, and decreasing cost of sequencing.
Currently, the cancer microbiome sequencing industry is witnessing an upsurge due to the increasing emphasis on the microbiome’s potential in the field of cancer, global increase in cancer prevalence, and decreasing cost of sequencing. Furthermore, biotechnology companies are focusing on developing cancer microbiome sequencing solutions for applications, including translational research and diagnostics, further supporting researchers and clinicians to unravel insights pertaining to microbiome's influence on cancer manifestation and progression. The development of cancer microbiome sequencing products and services enabled the research community to establish effective strategies for discovering novel cancer biomarkers associated with the microbiome, which could be harnessed for the development of cancer microbiome sequencing products for clinical use.
Within the research report, the market is segmented on the basis of offering, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the number of cancer cases worldwide has created a buzz among the biotechnology companies to further invest in the development of novel diagnostic tools based on microbiome for supporting physicians to offer early cancer detection. Due to the expansive product portfolio and massive geographical presence, Illumina, Inc. has been the leading player in the cancer microbiome sequencing ecosystem.
On the basis of region, North America holds the largest share of the cancer microbiome sequencing market due to the presence of market leaders such as Illumina, Inc. in the U.S. coupled with the significant adoption of high-fidelity cancer microbiome sequencing products and services for translational research. Further, rising fund infusions by the federal organizations and increasing investments for product development, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2021-2031. This is majorly attributed to the underlying factors such as an increase in healthcare awareness, steady economy leading to higher focus on research, and widespread adoption of advanced cancer diagnostics, among others.
Cancer Microbiome Sequencing Market - A Global and Regional Analysis
Focus on Offering, Application, Technology, End User, and Region - Analysis and Forecast, 2021-2031
Some Faq's
Frequently Asked Questions
The global market for cancer microbiome sequencing is predicted to grow at a CAGR of 20.01% over the forecast period of 2021-2031.
The top market players are CD Genomics, Eurofins Scientific, GoodGut, Illumina, Inc., Prescient Medicine Holdings, Inc., Micronoma Inc., Novogene Co., Ltd., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Viome, Inc., Zymo Research Corporation.
Factors driving the growth of the cancer microbiome sequencing market are increasing emphasis on the microbiome’s potential in the field of cancer, global increase in cancer prevalence, and decreasing cost of sequencing.
Some of the main challenges restricting the growth of the cancer microbiome sequencing market are regulatory challenges for direct-to-consumer (DTC) companies, lack of high complexity testing centers, and existing diagnostic confidence in conventional cancer diagnostics.
The potential opportunities that are likely to boost the growth of the cancer microbiome sequencing market are the growing integrative industry-academia collaboration and massive scope for the adoption of cancer microbiome sequencing in developing nations.
Similar Product
You may also like
Published Year: 2020
Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competi
The global market for microbiome therapeutics is predicted to grow at a CAGR of 25.64% over...
Published Year: 2020
Global Human Microbiome Sequencing Market: Focus on Products, Technologies, Applications, End Users,
The Global Human Microbiome Sequencing Market Report by BIS Research projects the market to...